Oxford BioSciences Jonathan Fleming And Chris Kim On Investing in Korea: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
All eyes are on the Korea-Seoul Life Science Fund to see how the collaboration between the Boston-based venture capital firm Oxford Biosciences, Korea’s Hanwha Venture Capital, the Seoul Metropolitan Government and the Korea Institute for Advancement of Technology under the Ministry of Knowledge Economy will evolve.
You may also be interested in...
SEOUL - Merck & Co. has become a leader in the race to bring a low-cost version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept) to the market after gaining rights to a late-stage biosimilar version of the biologic developed by South Korea's Hanwha Chemical Corporation
NEW YORK - Oxford Bioscience Partners has chosen Korea as its first Asian country to invest in via a partnership with Hanwha Venture Capital in Seoul
SEOUL - South Korean President Lee Myung-bak named "17 new growth engines" at a science and technology council meeting at his office in Seoul Jan. 13. Expected to spearhead the country's economic growth for the next 10 years, of those 17 economic growth engines, the Korean government targeted biologics, medical devices and global health care among the national priorities